{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100.00","upperLimit":"100.00","value":"100.00"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.4","upperLimit":"99.7","value":"98.0"}]}],"title":"24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.4","upperLimit":"99.7","value":"98.0"}]}],"title":"36 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.4","upperLimit":"99.7","value":"98.0"}]}],"title":"48 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.0","upperLimit":"98.0","value":"93.8"}]}],"title":"60 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of the first dose of study drug to the date of death. Subjects who were alive at the time of discontinuation/completion of the study were censored at the end of study date or end of treatment visit date if the subject refused to be followed post treatment. Full analysis set.","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects received in tablet form imatinib (STI571) 400 mg once daily.","id":"OG000","title":"Imatinib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Baseline up to appoximately 60 months","title":"Kaplan-Meier Estimates for Overall Survival (OS) up to 60 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}